白內(nèi)障的防治一直是防盲治盲工作的重點(diǎn)，但其發(fā)病機(jī)制尚不完全清楚，目前臨床上還缺少有效的治療藥物。構(gòu)建及選擇合適的白內(nèi)障動(dòng)物模型不僅是深入研究白內(nèi)障發(fā)病機(jī)制的重要基礎(chǔ)，也是臨床篩選和評(píng)價(jià)防治白內(nèi)障藥物的有效手段。因此就近年來國(guó)內(nèi)外有關(guān)人工誘導(dǎo)性和先天性白內(nèi)障動(dòng)物模型的構(gòu)建方式、特點(diǎn)及在藥物評(píng)價(jià)研究發(fā)面的應(yīng)用進(jìn)行綜述，并總結(jié)基于不同藥理機(jī)制的抗白內(nèi)障藥物研究進(jìn)展，提出目前應(yīng)增加晶狀體聚集蛋白溶解藥物的發(fā)現(xiàn)，以期推動(dòng)白內(nèi)障藥物治療的發(fā)展。

The prevention and treatment of cataract has always been the focus of prevention and treatment of blindness, but its pathogenesis is still not completely clear, and there is still a lack of effective therapeutic drugs in clinical practice. Constructing and selecting appropriate cataract animal models is not only an important basis for in-depth study of the pathogenesis of cataract, but also an effective means for clinical screening and evaluation of anti-cataract drugs. Therefore, this paper reviews the construction methods, characteristics and application in drug evaluation of animal models of artificially induced and congenital cataracts at home and abroad in recent years, summarizes the research progress of anti-cataract drugs based on different pharmacological mechanisms, and proposes that the discovery of crystalloid aggregate protein dissolving drugs should be increased at present, in order to promote the development of cataract drug therapy.

R965.1;R988.1

江蘇省創(chuàng)新能力建設(shè)計(jì)劃科技公共服務(wù)平臺(tái)項(xiàng)目(BM2021002)